A detailed history of Sigma Planning Corp transactions in Novo Nordisk A S stock. As of the latest transaction made, Sigma Planning Corp holds 15,597 shares of NVO stock, worth $1.36 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
15,597
Previous 16,564 5.84%
Holding current value
$1.36 Million
Previous $2.36 Million 21.45%
% of portfolio
0.06%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

SELL
$119.07 - $145.42 $115,140 - $140,621
-967 Reduced 5.84%
15,597 $1.86 Million
Q2 2024

Aug 05, 2024

SELL
$122.71 - $146.91 $45,648 - $54,650
-372 Reduced 2.2%
16,564 $2.36 Million
Q1 2024

May 01, 2024

BUY
$102.11 - $135.92 $745,300 - $992,080
7,299 Added 75.74%
16,936 $2.17 Million
Q4 2023

Feb 01, 2024

SELL
$87.78 - $105.45 $168,800 - $202,780
-1,923 Reduced 16.63%
9,637 $996,000
Q3 2023

Nov 06, 2023

BUY
$90.94 - $199.54 $781,538 - $1.71 Million
8,594 Added 289.75%
11,560 $1.05 Million
Q2 2023

Aug 01, 2023

BUY
$155.98 - $172.65 $137,106 - $151,759
879 Added 42.12%
2,966 $479,000
Q1 2023

May 05, 2023

SELL
$132.34 - $159.14 $40,893 - $49,174
-309 Reduced 12.9%
2,087 $332,000
Q4 2022

Jan 24, 2023

SELL
$102.55 - $135.33 $29,944 - $39,516
-292 Reduced 10.86%
2,396 $0
Q3 2022

Nov 10, 2022

SELL
$95.28 - $116.93 $17,912 - $21,982
-188 Reduced 6.54%
2,688 $268,000
Q2 2022

Aug 11, 2022

BUY
$103.24 - $121.81 $44,599 - $52,621
432 Added 17.68%
2,876 $321,000
Q1 2022

Apr 20, 2022

SELL
$93.1 - $112.54 $2,234 - $2,700
-24 Reduced 0.97%
2,444 $271,000
Q4 2021

Feb 02, 2022

BUY
$95.88 - $117.08 $9,588 - $11,708
100 Added 4.22%
2,468 $276,000
Q3 2021

Oct 28, 2021

BUY
$84.42 - $106.62 $199,906 - $252,476
2,368 New
2,368 $227,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.